Cargando…

Advantages of Phosphodiesterase Type 5 Inhibitors in the Management of Glucose Metabolism Disorders: A Clinical and Translational Issue

Among metabolic diseases, carbohydrate metabolism disorders are the most widespread. The most common glucose pathological conditions are acquired and may increase the risk of type 2 diabetes, obesity, heart diseases, stroke, and kidney insufficiency. Phosphodiesterase type 5 inhibitors (PDE5i) have...

Descripción completa

Detalles Bibliográficos
Autores principales:	Antinozzi, Cristina, Sgrò, Paolo, Di Luigi, Luigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407035/ https://www.ncbi.nlm.nih.gov/pubmed/32774364 http://dx.doi.org/10.1155/2020/7078108

Ejemplares similares

The Phosphodiesterase Type 5 Inhibitor Sildenafil Improves DNA Stability and Redox Homeostasis in Systemic Sclerosis Fibroblasts Exposed to Reactive Oxygen Species
por: Di Luigi, Luigi, et al.
Publicado: (2020)

Tadalafil and Steroid Hormones Interactions in Adipose, Bone and Prostate Tissues: Focus on Translational Perspectives
por: Greco, Emanuela Alessandra, et al.
Publicado: (2022)

The phosphodiesterase 5 inhibitor sildenafil decreases the proinflammatory chemokine IL-8 in diabetic cardiomyopathy: in vivo and in vitro evidence
por: Giannattasio, S., et al.
Publicado: (2018)

Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy
por: Di Luigi, Luigi, et al.
Publicado: (2016)

Sildenafil Counteracts the In Vitro Activation of CXCL-9, CXCL-10 and CXCL-11/CXCR3 Axis Induced by Reactive Oxygen Species in Scleroderma Fibroblasts
por: Antinozzi, Cristina, et al.
Publicado: (2021)

The first‐generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue
por: Zucchi, A., et al.
Publicado: (2019)

Effect of Tadalafil Administration on Redox Homeostasis and Polyamine Levels in Healthy Men with High Level of Physical Activity
por: Duranti, Guglielmo, et al.
Publicado: (2021)

Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications
por: Corinaldesi, C., et al.
Publicado: (2015)

Sildenafil Reduces Expression and Release of IL-6 and IL-8 Induced by Reactive Oxygen Species in Systemic Sclerosis Fibroblasts
por: Di Luigi, Luigi, et al.
Publicado: (2020)

Exploratory Analysis in the Differences in Blood Serum and Seminal Plasma of Adipose-Tissue Related Peptides in Obese and Non-Obese Men and Their Correlations With Semen Parameters
por: Antinozzi, Cristina, et al.
Publicado: (2021)

Hydrogen Peroxide Stimulates Dihydrotestosterone Release in C2C12 Myotubes: A New Perspective for Exercise-Related Muscle Steroidogenesis?
por: Antinozzi, Cristina, et al.
Publicado: (2022)

Systemic Response of Antioxidants, Heat Shock Proteins, and Inflammatory Biomarkers to Short-Lasting Exercise Training in Healthy Male Subjects
por: Dimauro, Ivan, et al.
Publicado: (2021)

Evolution of Phosphodiesterase-5 Inhibitors
por: Moon, Du Geon
Publicado: (2015)

The Prostacyclin Analogue Iloprost Modulates CXCL10 in Systemic Sclerosis
por: Colasanti, Tania, et al.
Publicado: (2022)

Testosterone insulin-like effects: an in vitro study on the short-term metabolic effects of testosterone in human skeletal muscle cells
por: Antinozzi, C., et al.
Publicado: (2017)

Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants
por: Tiwari, Amit K., et al.
Publicado: (2013)

Taking Advantage of the Selectivity of Histone Deacetylases and Phosphodiesterase Inhibitors to Design Better Therapeutic Strategies to Treat Alzheimer’s Disease
por: Cuadrado-Tejedor, Mar, et al.
Publicado: (2019)

Phosphodiesterase-5 inhibitors for colon cancer chemoprevention
por: Islam, Bianca N., et al.
Publicado: (2018)

Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?
por: Hutchings, David Charles, et al.
Publicado: (2018)

Phosphodiesterase-5 inhibitors: Emerging nephroprotective drugs
por: Abassi, Zaid, et al.
Publicado: (2015)

The Preventive Role of Physical Activity in Systemic Sclerosis: A Cross-Sectional Study on the Correlation with Clinical Parameters and Disease Progression
por: Antinozzi, Cristina, et al.
Publicado: (2022)

Translational Development Strategies for TAK-063, a Phosphodiesterase 10A Inhibitor
por: Macek, Thomas A, et al.
Publicado: (2020)

Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy
por: Buckley, Mitchell S, et al.
Publicado: (2010)

Peyronie's Disease: Evolving Surgical Management and the Role of Phosphodiesterase 5 Inhibitors
por: Al-Shaiji, Tariq F., et al.
Publicado: (2009)

Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management?
por: Mondaini, Nicola
Publicado: (2020)

AB030. Evolution of phosphodiesterase type 5 inhibitors
por: Moon, Du Geon
Publicado: (2016)

The Wonders of Phosphodiesterase-5 Inhibitors: A Majestic History
por: Elhwuegi, AS
Publicado: (2016)

COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2020)

Determination of Phosphodiesterase Type-5 Inhibitors (PDE-5) in Dietary Supplements
por: Gheorghiu, Oana Ramona Cătălina, et al.
Publicado: (2023)

Phosphodiesterase-5 inhibitors have distinct effects on the hemodynamics of the liver
por: Halverscheid, Leonie, et al.
Publicado: (2009)

The role of phosphodiesterase-5 inhibitors in prostatic inflammation: a review
por: Peixoto, Christina Alves, et al.
Publicado: (2015)

Pharmacophore elucidation and molecular docking studies on phosphodiesterase-5 inhibitors
por: Radwan, Awwad Abdoh
Publicado: (2015)

Phosphodiesterase type 5 inhibitors: Irrational use in Saudi Arabia
por: Alshahrani, Saad, et al.
Publicado: (2016)

Contribution of sewage to occurrence of phosphodiesterase-5 inhibitors in natural water
por: Hong, Youngmin, et al.
Publicado: (2021)

Phosphodiesterase Type 5 Inhibitors and sudden sensorineural hearing loss
por: Barreto, Monique Antunes de Souza Chelminski, et al.
Publicado: (2015)

Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives
por: ElHady, Ahmed K., et al.
Publicado: (2023)

Coupling of conformational dynamics and inhibitor binding in the phosphodiesterase‐5 family
por: Tripathi, Shubhandra, et al.
Publicado: (2023)

Effect of phosphodiesterase inhibitors in the bladder
por: Chughtai, Bilal, et al.
Publicado: (2015)

Phosphodiesterase-5 Inhibitor Attenuates Anxious Phenotypes and Movement Disorder Induced by Mild Ischemic Stroke in Rats
por: Yu, Yeon Hee, et al.
Publicado: (2022)

Metabolic effects of phosphodiesterase III inhibitors: another reason to promote their use?
por: Simkova, Vladislava, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_micfggg2t21n5n1eq9cqobqgmr